| Objective:To study the therapeutic effects of Guiqi Granule on hepatic fibrosis in model rat.Contents and Methods:1. To compare the different preparing mathods in pharmacodynamics. The model of hepatic fibrosis in rats was made with carbon tetrachloride. Fibrosis model was induced in male rats by 15% CCl4 edible oily solution per oral biweekly at dose of 10mL/kg body weight for 10 weeks. Then the model rats were randomly divided into model control group, positive control group and Guiqi granule Sample 1,2 and 3 groups with same dose. Another normal control group was set up with normal rats. The rats of Guiqi granule groups were treated with Guiqi granule per oral from the 9th week for 8 weeks with the dosages of 22.4g/kg (calculated by raw materials). The rats of positive control group were treated by Fu-Zheng-Hua-Yu Capsule at dose 0.825 g/kg per oral for same time. The normal control group and the model control group were given sterile drinking water at the same volume and same time. At the second day of the last orally, the blood samples were taken to determine the changes of following serological parameters (ALT, AST, HA, PIIINP) and the concentration of Hyp in liver tissue. Then liver tissue samples were taken to pathological sections for observing the changes of hepatic fibrosis.2. To study the therapeutic effects of Guiqi Granule on hepatic fibrosis in CCI4 model rats. Fibrosis model was made in male rats by 15% CCl4 edible oily solution per oral biweekly at dose of lOmL/kg body weight for 16 weeks. Then the model rats were randomly divided into model control group, positive control group and 3 Guiqi granule groups with high, middle and low dose. Another normal control group was set up with normal rats. The rats of Guiqi granule groups were treated with Guiqi granule per oral from the 9th week for 8 weeks with the dosages of 22.4,11.2 and 5.6g/kg (calculated by raw materials). The rats of positive control group were treated by Fu-Zheng-Hua-Yu Capsule at dose 0.825 g/kg per oral for same time. The normal control group and the model control group were given sterile drinking water at the same volume and same time of the other groups. At the second day of the last orally treated, the blood samples were taken to determine the changes of following serological parameters (ALT, AST, T-BIL, ALP, TP, ALB, GLB, HA, CIV and PⅢNP) and the concentration of Hyp in liver tissue. Then liver tissue samples were taken to pathological sections for observing the changes of hepatic fibrosis. The method of immunohistochemistry was used to detect the expressions of TGF-β1 in the liver tissue.3. To study the therapeutic effects of Guiqi Granule on hepatic fibrosis in Porcine serum model rats. Fibrosis model was induced in rats by intraperitoneal injection with Porcine serum biweekly at dose of 0.5mL/time for 16 weeks. At the 9th week, the model rats were randomly divided into model control group, positive control group and 3 Guiqi granule groups with high, middle and low dose. Another normal control group was set up with normal rats. The rats of Guiqi granule groups were treated with Guiqi granule per oral from the 9th week for 8 weeks with the dosages of 22.4,11.2 and 5.6g/kg (calculated by raw materials). The rats of positive control group were treated by Fu-Zheng-Hua-Yu Capsule at dose 0.825 g/kg per oral for same time. The normal control group and the model control group were given sterile drinking water at the same volume and same time of the other groups. At the second day of the last orally treated, the blood samples were taken to determine the changes of following serological parameters (ALT, AST, T-BIL, ALP, TP, ALB, GLB, HA, CⅣand PⅢNP) and the concentration of Hyp in liver tissue. Then liver tissue samples were taken to pathological sections for observing the changes of hepatic fibrosis.4. Cholagogic test:After taking Guiqi Granule per oral, the choleretic effect was accessed by measuring the amount of bile secretion in normal rats and the content of total bilirubin. Results:1. Guiqi granule Sample 1 could obviously decrease the levels of ALT, AST, HA and PⅢNP in rats serum with experimental hepatic fibrosis model. It could evidently decrease the concentration of Hyp in liver tissue too, and could obviously relieve the pathological damage of liver tissues. It is better than other two samles.2. Guiqi granule could obviously decrease the levels of AST, ALP and HA in rats serum with experimental hepatic fibrosis model. It could evidently decrease the concentration of Hyp in liver tissue too, and could obviously relieve the pathological damage of liver tissues.3. The immuno-histochemical examinations showed that the expression of TGF-β1 was induced in the hepatocytes with chronic damage by CCl4. Comparing with the model group, the expressions of TGF-β1 were brought back to control levels by using Guiqi granule.4. The bile secretion of rats could be promoted by administrating Guiqi granule. And the content of total bilirubin in rats was increased obviously.Conclusion:Guiqi granule could evidently improve the symptoms of hepatic fibrosis in rat model. The mechanism may relate with the decreasing of TGF-β1 in liver tissue.
|
PDF Full Text Request